# Analysis of Pharmacist Interventions to Reduce Medication-Related Problems in a Neonatal Clinical Care Unit

**Authors:** Stephanie W. K. Teoh, Tamara Lebedevs, Geena Dickson, Marcus Femia, Nabeelah Mukadam

PMC · DOI: 10.3390/pharmacy14020040 · 2026-03-02

## TL;DR

This study examines pharmacist interventions in a neonatal care unit to identify and reduce medication-related problems, showing common issues like dosing errors and policy compliance.

## Contribution

The study provides a detailed analysis of pharmacist interventions in a neonatal clinical care unit to guide targeted medication safety improvements.

## Key findings

- Dosing errors were the most common medication-related problem (36.7%).
- Pharmacists' interventions were accepted by prescribers in 62.4% of cases.
- Gentamicin and benzylpenicillin were among the most frequently involved medications in interventions.

## Abstract

(1) Background: Medication-related problems (MRPs) are a significant burden on health care systems. Pharmacists play an important role in preventing and reducing MRPs through clinical review, education, and policy governance. This study analyzed pharmacist interventions within a 92-bed neonatal clinical care unit to better understand MRPs and guide targeted medication safety initiatives. (2) Methods: All pharmacist interventions documented in REDCap® between 1 July 2022 and 30 June 2025 were analyzed identifying MRP incidence, types, and acceptability following interventions. (3) Results: A total of 873 pharmacist interventions were recorded during the study period. The most common MRPs were related to dosing errors (320/873, 36.7%), compliance with hospital policy (152/873, 17.4%), no indication apparent (106/873, 12.1%), drug interactions (66/873, 7.6%), and inadequate laboratory monitoring (40/873, 4.6%). Of these, 545/873, 62.4% were accepted by prescribers, while 228/873, 26.1% had unknown outcomes at the time of data entry. 343/873, 39.3% of interventions documented were from the Neonatal Intensive Care Unit, involving medications such as gentamicin (n = 46/343, 13.4%), benzylpenicillin (n = 37/343, 10.8%), caffeine (n = 34/343, 9.9%), parenteral nutrition (n = 23/343, 6.7%), and morphine (n = 16/343, 4.7%) and meropenem (n = 16/343, 4.7%)). (4) Conclusions: Regular analysis of pharmacist interventions provides valuable insights into local MRP trends and highlights opportunities for quality improvement and education.

## Linked entities

- **Chemicals:** gentamicin (PubChem CID 3467), benzylpenicillin (PubChem CID 5904), caffeine (PubChem CID 2519), morphine (PubChem CID 5288826), meropenem (PubChem CID 441130)

## Full-text entities

- **Diseases:** overdoses (MESH:D062787), injury to (MESH:D014947), MRPs (MESH:D000076082)
- **Chemicals:** meropenem (MESH:D000077731), morphine (MESH:D009020), magnesium sulfate (MESH:D008278), caffeine (MESH:D002110), paracetamol (MESH:D000082), benzylpenicillin (MESH:D010400), Coconut oil (MESH:D000074263), vancomycin (MESH:D014640), dobutamine (MESH:D004280), iron (MESH:D007501), caspofungin (MESH:D000077336), dexamethasone (MESH:D003907), alprostadil (MESH:D000527), gentamicin (MESH:D005839)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC13010683/full.md

---
Source: https://tomesphere.com/paper/PMC13010683